Cronos Group (CRON) Competitors

Cronos Group (NASDAQ:CRON) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership, community ranking and earnings.

Do analysts recommend CRON or APLS?

Cronos Group currently has a consensus target price of $3.00, suggesting a potential upside of 35.75%. Apellis Pharmaceuticals has a consensus target price of $70.20, suggesting a potential upside of 158.66%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cronos Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Apellis Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.80

Which has more risk and volatility, CRON or APLS?

Cronos Group has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.

Does the MarketBeat Community prefer CRON or APLS?

Cronos Group received 131 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. However, 67.82% of users gave Apellis Pharmaceuticals an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.

Company	Underperform	Outperform
Cronos Group	Outperform Votes 464 61.13%	Underperform Votes 295 38.87%
Apellis Pharmaceuticals	Outperform Votes 333 67.82%	Underperform Votes 158 32.18%

Do institutionals & insiders have more ownership in CRON or APLS?

8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by company insiders. Comparatively, 6.8% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media favor CRON or APLS?

In the previous week, Apellis Pharmaceuticals had 9 more articles in the media than Cronos Group. MarketBeat recorded 12 mentions for Apellis Pharmaceuticals and 3 mentions for Cronos Group. Apellis Pharmaceuticals' average media sentiment score of 0.79 beat Cronos Group's score of 0.74 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cronos Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apellis Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Is CRON or APLS more profitable?

Apellis Pharmaceuticals has a net margin of -52.99% compared to Cronos Group's net margin of -56.43%. Cronos Group's return on equity of -2.06% beat Apellis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cronos Group	-56.43%	-2.06%	-1.99%
Apellis Pharmaceuticals	-52.99%	-138.32%	-39.63%

Which has stronger valuation & earnings, CRON or APLS?

Cronos Group has higher earnings, but lower revenue than Apellis Pharmaceuticals. Cronos Group is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cronos Group	$87.24M	9.68	-$73.96M	-$0.15	-14.73
Apellis Pharmaceuticals	$396.59M	8.33	-$528.63M	-$2.74	-9.91

Summary

Apellis Pharmaceuticals beats Cronos Group on 11 of the 19 factors compared between the two stocks.